A comparison of clinical pathologic characteristics between alpha-fetoprotein negative and positive hepatocellular carcinoma patients from Eastern and Southern China

• Main Authors: Chi, X. (Author), Hochwald, S. (Author), Huang, H. (Author), Huang, X. (Author), Jiang, L. (Author), Liu, J. (Author), Yang, X. (Author), Yuan, Y. (Author)
• Format: Article
• Language: English
• Published: BioMed Central Ltd 2022
• Subjects: alpha fetoprotein; Alpha-fetoprotein (AFP); alpha-Fetoproteins; bilirubin; Bilirubin; biological marker; Biomarkers; Biomarkers, Tumor; Carcinoembryonic antigen (CEA); Carcinoma, Hepatocellular; Chronic hepatitis B; gamma glutamyltransferase; gamma-Glutamyltransferase; Hepatitis B virus DNA (HBV DNA); Hepatocellular carcinoma (HCC); human; Humans; liver cell carcinoma; liver cirrhosis; Liver cirrhosis; Liver Cirrhosis; Liver Neoplasms; liver tumor; metabolism; Neutrophil to lymphocyte ratio (NLR); pathology; Protein induced vitamin K absence or antagonist-II (PIVKA-II); protein precursor; Protein Precursors; prothrombin; Prothrombin; receiver operating characteristic; ROC Curve; tumor marker
• Online Access: View Fulltext in Publisher

 Background: Alpha-fetoprotein (AFP) is a biomarker used in clinical management of hepatocellular carcinoma (HCC), however, approximately 40% of HCC patients do not present with elevated serum AFP levels. This study aimed to investigate the clinical and pathologic characteristics between AFP positive and negative HCC patients to allow for improved clinical management and prognostication of the disease. Methods: This study observed a cohort of HCC patients from Eastern and Southern China with comparisons of the clinical and pathologic features between serum AFP positive and negative patient groups; patients with decompensated hepatic cirrhosis, those with chronic hepatitis B, and hepatitis B virus (HBV) asymptomatic carrier patients were used as controls. Data included the laboratory results, pathology diagnosis, clinical staging and scores were obtained from routine clinical diagnostic methods. Results: Patients with HCC, larger tumor sizes, liver cancer with hepatic cirrhosis, portal vein thrombosis, metastasis, high Child–Pugh score, high Barcelona-Clínic Liver Cancer (BCLC) stage, and advanced clinical stage had significantly higher serum AFP levels. Also, patients with HBsAg and HBeAg positive, high HBV DNA levels had significantly higher serum AFP levels. Patients with high serum AFP levels had higher protein induced by vitamin K absence or antagonist-II (PIVKA-II), alanine aminotransferase (ALT), aspartate aminotransferase (AST), alpha-l-fucosidase (AFU), gamma-glutamyl transpeptidase (γ-GT), γ-GT /ALT, direct bilirubin (DBIL), indirect bilirubin (IDBIL), fibrinogen, and D-dimer levels. Patients with AFP positive had higher white blood cells (WBC), neutrophil, monocyte, and platelet count and neutrophil to lymphocyte ratio (NLR). Conclusions: The are significant differences in clinical pathologic characteristics between AFP positive and negative HCC patients which may be helpful for the management and prognostication of the disease. © 2022, The Author(s).